A Phase 3, Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Ankylosing Spondylitis.
Phase of Trial: Phase III
Latest Information Update: 24 Jun 2011
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis
- Focus Pharmacodynamics; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 24 Jun 2011 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
- 12 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History